Anti-rheumatic drug as a potential candidate for treating COVID-19

anti rheumatic drug as a potential candidate for treating covid 19

Sumary of Anti-rheumatic drug as a potential candidate for treating COVID-19:

  • The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces inflammatory cytokine storms.
  • But an FDA-approved anti-rheumatic drug, Auranofin, used to treat autoimmune and infectious diseases, may also help serve as an antiviral treatment for COVID-19 infection.
  • In a new research article, Karine Sonzogni-Desautels and Momar Ndao of the Research Institute of the McGill University Health Centre in Canada make a case for Auranofin based on the drug’s mechanism of action and anti-inflammatory properties via the NF-kBIL-6-STAT3 signaling pathway.
  • The researchers write: “An orally-administered FDA-approved drug with anti-inflammatory and anti-SARS-CoV-2 properties with an acceptable toxicity profile would offer significant benefits for the control of the COVID-19 pandemic.
  • ” The study “Will Auranofin Become a Golden New Treatment Against COVID-19?” was recently published in the medical journal Frontiers in Immunology.
  • Auranofin inhibits several key players in the NF-kB-IL-6-STAT3 signaling pathway Auranofin helps minimize oxidative stress and increases cell survival by inhibiting the thioredoxin reductase enzyme.
  • By reducing thioredoxin reductase, Auranofin inhibits NF-kB-dependent gene expression.
  • Auranofin is advantageous for its ability to reduce IL-6 expression through inhibition of NF-kb in SARS-CoV-2 infected cells.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.